Search Results
Your search for ,led matches 5952 pages
Showing 651 - 700Enobosarm in Previously Treated Patients With AR-Positive, ER-Positive, HER2-Negative Advanced Breast Cancer
In a phase II trial (Study G200802) reported in The Lancet Oncology, Palmieri et al found that the novel selective androgen receptor (AR) modulator enobosarm was active in previously treated patients with AR-positive, estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic...
Perioperative Tislelizumab Plus Chemotherapy in Resectable NSCLC
In patients with resectable non–small cell lung cancer (NSCLC), perioperative treatment with the checkpoint inhibitor tislelizumab plus platinum-doublet chemotherapy led to a statistically significant benefit in event-free survival and a favorable trend for overall survival, investigators for the...
Venetoclax Plus Azacitidine Evaluated in High-Risk Myelodysplastic Syndromes
For the treatment of high-risk, treatment-naive myelodysplastic syndromes (MDS), the regimen of venetoclax plus azacitidine led to high response rates, durable responses, and encouraging overall survival, in a phase Ib study reported at the 2023 American Society of Hematology (ASH) Annual Meeting...
First-Line Ruxolitinib Combinations Boost Benefit Over Single Agent in Myelofibrosis
In two international phase III trials in myelofibrosis, drugs given in combination with the Janus kinase (JAK) inhibitor ruxolitinib in JAK inhibitor–naive patients significantly improved outcomes vs ruxolitinib alone. Both studies were presented at the 2023 American Society of Hematology Annual...
‘Ultra-Low Dose’ of Radiotherapy May Be Enough in Gastric MALT Lymphoma, Study Finds
For patients with gastric MALT (mucosa-associated lymphoid tissue) lymphoma, an “ultra-low dose” of radiotherapy was as effective as the higher, standard dose in providing local control and freedom from distant relapse, researchers from The University of Texas MD Anderson Cancer Center reported at...
Expert Point of View: Peter Voorhees, MD
Peter Voorhees, MD, a multiple myeloma specialist at Levine Cancer Institute and Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Durham, North Carolina, introduced the plenary presentation of the phase III IsKia trial by Gay et al and further commented on the study for The ASCO...
Addition of Isatuximab to Carfilzomib-Based Regimen Doubles MRD Negativity Rates in Multiple Myeloma
In the phase III IsKia trial in newly diagnosed multiple myeloma, therapy incorporating the CD38-directed monoclonal antibody isatuximab-irfc with a carfilzomib-based regimen led to high rates of minimal residual disease (MRD) negativity at postconsolidation cutoffs, as reported at the 2023...
Canadian Study Shows Myeloma Outcomes in the Real World May Be Worse Than Clinical Trials Suggest
Patients with multiple myeloma treated in the “real world” had worse outcomes than patients who received the same treatment on clinical trials, according to research presented at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition.1 In a pooled analysis of clinical trial...
Racial Representation Affects Trust for Black Patients Seeking Prostate Cancer Information Online
Among Black patients with prostate cancer, racial representation may be a key factor affecting their trust in websites offering information on the disease, according to a recent study published by Loeb et al in The Journal of Urology. Background Black men may have higher rates of prostate cancer...
Understanding the Discordance About Prognosis Between Clinicians and Terminally Ill Patients and Their Surrogates
Research shows that about half of adults near the end of life in the United States are too ill to participate in decisions about whether to accept life-prolonging treatment,1 requiring family members and other proxies to serve as surrogate decision-makers for their critically ill loved ones....
Crenolanib and Intensive Chemotherapy in Newly Diagnosed FLT3-Mutated AML
In a pilot study reported in the Journal of Clinical Oncology, Eunice S. Wang, MD, and colleagues found that the combination of crenolanib and intensive chemotherapy produced high response rates in adults with newly diagnosed FLT3-mutated acute myeloid leukemia (AML). Crenolanib is a...
DREAMM-7 Confirms Benefit of Triplet Regimen in Relapsed or Refractory Multiple Myeloma
Positive results were reported for belantamab mafodotin-blmf plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma, according to data from the phase III DREAMM-7 study presented at the ASCO Plenary Series: February 2024 Session (Abstract 439572). DREAMM-7...
Insufficiencies Discovered in Patient-Reported Outcomes Data From Genitourinary Cancer Clinical Trials
Investigators may have found a significant unmet need for improved analyses and reporting of patient-reported outcomes in genitourinary cancer clinical trials, according to a recent study published by Paravathaneni et al in eClinicalMedicine. Background Genitourinary cancers affect over 444,000...
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML
In a single-center phase I/II study reported in the Journal of Clinical Oncology, Nicholas J. Short, MD, and colleagues found that treatment with azacitidine, venetoclax, and gilteritinib produced a high response rate in newly diagnosed patients with FLT3-mutated acute myeloid leukemia (AML);...
Intensification of ADT in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer After Radical Prostatectomy
As reported in the Journal of Clinical Oncology by Aggarwal et al, interim analysis of the phase III PRESTO trial showed that the addition of apalutamide as well as the addition of apalutamide plus abiraterone acetate/prednisone (AAP) to androgen-deprivation therapy (ADT) improved prostate-specific ...
Golidocitinib in Relapsed or Refractory Peripheral T-Cell Lymphoma
In a phase II trial (JACKPOT8 Part B) reported in The Lancet Oncology, Song et al found that the selective JAK1 tyrosine kinase inhibitor golidocitinib showed activity in patients with relapsed or refractory peripheral T-cell lymphoma. Study Details In the trial, 104 patients from sites in...
Cardio-Oncology Is a Growing Subspecialty, but Where Are the Oncologists?
It has been almost 20 years since the approval of trastuzumab for the treatment of early-stage, HER2-positive breast cancer. I remember returning from the 2005 ASCO Annual Meeting excited to offer patients a treatment that led to significant improvement in clinical outcomes. However, within a short ...
Addition of Nivolumab to Chemotherapy in EGFR-Mutant Metastatic NSCLC After Disease Progression on Prior Therapy
As reported in the Journal of Clinical Oncology by Tony Mok, MD, FRCPC, FASCO, and colleagues, final results of the primarily Asian phase III CheckMate 722 trial showed no progression-free survival benefit with the addition of nivolumab to chemotherapy in patients with EGFR-mutant metastatic...
Reframing DCIS as an Opportunity for Cancer Prevention
We have been taught that early cancer detection and treatment save lives. The way to cure cancer is to find it early and treat it aggressively. The public has subscribed to this approach in our struggle to “eradicate cancer.” In certain disease types, there is merit to this philosophy. The ability...
Is HRR Testing Underused in Patients With Prostate Cancer?
Despite being recommended in prostate cancer guidelines, homologous recombinant repair (HRR) mutation analysis is widely underused in patients with prostate cancer, according to real-world data presented at the 2024 ASCO Genitourinary Cancers Symposium (Abstract 210). A major implication of these...
AMBASSADOR: Pembrolizumab in Muscle-Invasive and Locally Advanced Urothelial Carcinoma
Patients with muscle-invasive urothelial cancer and a high risk of recurrence after surgery may have a new treatment option. The Alliance for Clinical Trials in Oncology announced positive results from the phase III AMBASSADOR (A031501) trial for the adjuvant treatment of patients with localized...
Integrated Medicine and Collaborative Care: Innovations in Cancer Treatment and Mental Health Care
Recent studies by multidisciplinary teams at Memorial Sloan Kettering Cancer Center and Massachusetts General Hospital are illuminating novel ways to address health-care challenges faced by patients with cancer. The research, presented at the 2023 ASCO Quality Care Symposium, highlights the...
Neoadjuvant Chemoimmunotherapy Improves Pathologic Complete Response Rates in Subgroup Analysis of KEYNOTE-756
Pembrolizumab added to neoadjuvant chemotherapy followed by adjuvant pembrolizumab plus endocrine therapy improved pathologic complete responses in patients with early-stage, high-risk, estrogen receptor (ER)-positive, HER2-negative breast cancer, according to updated results of the phase III...
Canadian Study Shows Myeloma Outcomes in the Real World May Be Worse Than Clinical Trials Suggest
Patients with multiple myeloma treated in the “real world” had worse outcomes than patients who received the same treatment on clinical trials, according to research presented at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition.1 In a pooled analysis of clinical trial...
SYMPATICO Trial: Ibrutinib Plus Venetoclax Improves Progression-Free Survival in Relapsed Mantle Cell Lymphoma
The combination of ibrutinib and venetoclax has led to an improved progression-free survival rate in patients with relapsed or refractory mantle cell lymphoma (MCL), according to findings presented at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition.1 Interim analysis...
Personalized Ibrutinib-Plus-Venetoclax Therapy: New Treatment Standard for Chronic Lymphocytic Leukemia?
A time-limited approach based on measurable residual disease (MRD) response could signal a potential paradigm shift for front-line treatment of chronic lymphocytic leukemia (CLL), according to data presented at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition1 and...
My Breast Cancer Experience Has Led Me to Leverage My Expertise in Human-Centered Design to Transform Patient Care
The road to my breast cancer diagnosis in 2018 was long and tortuous. For 3 years leading up to the diagnosis, I had imaging scans and tissue biopsies every 3 months because of suspicious masses in my breasts. The uncertainty was so destabilizing that I was in a constant state of emotional unrest....
Use of Enzalutamide in Nonmetastatic Castration-Sensitive Prostate Cancer With Biochemical Recurrence
On November 16, 2023, the androgen receptor inhibitor enzalutamide was approved for use in patients with nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis.1 Supporting Efficacy Data Approval was based on the EMBARK trial (ClinicalTrials.gov...
Long-Term Follow-up of KEYNOTE-590: Benefit of Pembrolizumab Plus Chemotherapy Affirmed in Advanced Esophageal Cancer
Long-term follow-up of the phase III KEYNOTE-590 trial has confirmed the benefit of pembrolizumab plus chemotherapy in advanced esophageal cancer. As compared with chemotherapy alone, after a median follow-up of almost 59 months, patients treated with the chemoimmunotherapy combination were three...
First-Line Nivolumab Plus Ipilimumab Shows Benefit in Metastatic Colorectal Cancer Subset
In the phase III CheckMate 8HW trial, previously untreated patients with microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) metastatic colorectal cancer derived significant benefit from an immunotherapy doublet of nivolumab plus ipilimumab in the first-line setting, which...
AUGMENT-101 Trial: Menin Inhibitor Revumenib Shows Activity in KMT2A-Rearranged Acute Leukemia
In heavily pretreated patients with a challenging type of acute leukemia, the menin inhibitor revumenib demonstrated clinically meaningful activity, including high rates of response and measurable residual disease (MRD) negativity, according to the efficacy and safety results of the phase II...
New Director of the University of Hawaii Cancer Center, Naoto T. Ueno, MD, PhD, FACP, Is Also a Two-Time Cancer Survivor
In this installment of The ASCO Post ’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Naoto T. Ueno, MD, PhD, FACP, Director of the University of Hawaii Cancer Center. Along with his duties leading the cancer center, Dr. Ueno leads translational breast cancer research...
Celebrating Excellence: Matthijs Oudkerk, PhD, MD, MSc, Honored for Contributions to Cancer Prevention and Research
The Prevent Cancer Foundation has honored Matthijs Oudkerk, PhD, MD, MSc, with the prestigious James L. Mulshine, MD, International Leadership Award. Dr. Oudkerk is Professor of Radiology at the University of Groningen and Chief Scientific Officer of the Institute for Diagnostic Accuracy in the...
Investigators Highlight Characteristics Potentially Linked to Improved CAR T-Cell Therapy Outcomes in Large B-Cell Lymphoma
Investigators have assessed whether specific tumor characteristics were associated with improved outcomes in patients with large B-cell lymphoma who received chimeric antigen receptor (CAR) T-cell therapy, according to a recent study published by Locke et al in Nature Medicine. The findings may...
ALL in Adults: Trial Updates and Clinical Considerations for Selecting Consolidation Therapy
Although pediatric patients with acute lymphoblastic leukemia (ALL) have seen a dramatic improvement in long-term survival rates over the past 40 years, from approximately 10% to over 95%, adults aged 29 and older have not experienced the same treatment benefits, with survival rates still below...
Long-Term Follow-up Supports Postneoadjuvant T-DM1 Over Trastuzumab in Early, High-Risk, HER2-Positive Breast Cancer
At a median follow-up of 8.4 years, adjuvant use of ado-trastuzumab emtansine (T-DM1) continued to improve invasive disease–free survival and overall survival compared with trastuzumab in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant therapy. These ...
Novel Vaccine May Delay Relapse in KRAS-Mutated Pancreatic and Colorectal Cancers
A novel vaccine may be effective at preventing relapse in patients with KRAS-mutated pancreatic and colorectal cancers, according to a recent study published by Pant et al in Nature Medicine. Background KRAS-mutated cancers make up about 25% of all solid tumors, including 90% of pancreatic cancer...
Perioperative Pembrolizumab Plus Chemotherapy in Locally Advanced Gastric/Gastroesophageal Cancer
As reported in The Lancet Oncology by Kohei Shitara, MD, and colleagues, interim analyses of the phase III KEYNOTE-585 trial have shown that the addition of perioperative pembrolizumab to chemotherapy improved pathologic complete response, but did not significantly improve event-free survival, in...
Phase III Trial Shows Novel Four-Drug Regimen Improves Survival Outcomes in Extensive-Stage Small Cell Lung Cancer
The addition of anlotinib to immunochemotherapy has achieved the historically longest progression-free survival and overall survival in the first-line setting of extensive-stage small cell lung cancer, according to data presented at the International Association for the Study of Lung Cancer 2023...
Addition of Atezolizumab to Bevacizumab and Chemotherapy in Metastatic, Persistent, or Recurrent Cervical Cancer
As reported in The Lancet by Ana Oaknin, MD, and colleagues, the phase III BEATcc trial has shown that the addition of atezolizumab to bevacizumab and chemotherapy improved progression-free and overall survival in women with metastatic, persistent, or recurrent cervical cancer. Study Details The...
NIH Immunotherapy Pioneer Steven A. Rosenberg, MD, PhD, Awarded Nation’s Highest Honor for Technology and Innovation
Immunotherapy pioneer Steven A. Rosenberg, MD, PhD, has been awarded the National Medal of Technology and Innovation by President Biden. It is the nation’s highest honor for technological achievement. Dr. Rosenberg is Chief of the Surgery Branch at the Center for Cancer Research at the National...
Neoadjuvant/Adjuvant Pembrolizumab in Resectable NSCLC
On October 16, 2023, pembrolizumab was approved for use with platinum-containing chemotherapy as neoadjuvant treatment and as single-agent adjuvant treatment in patients with resectable (tumors ≥ 4 cm or node-positive) non–small cell lung cancer (NSCLC).1 Supporting Efficacy Data Approval was based ...
Implementation of Updated WHO Screening Guidelines Could Reduce Cervical Cancer Mortality by Over 50% in Lower-Income Countries
Investigators have found that implementing the updated World Health Organization (WHO) screening guidelines may effectively reduce the cervical cancer mortality rate in patients residing in low- and middle-income countries, according to two recent studies published by Simms et al and Hall et al in...
The Power of Patient Advocacy: 10-Year Study Reveals Increased Survival Rates With Enhanced Advance Care Planning
A decade-long journey toward improving end-of-life care for patients with advanced cancer has demonstrated positive effects on survival, health-care use, and cost of care, according to data presented at the 2023 ASCO Quality Care Symposium.1 Post hoc analysis of an advance care planning...
Expert Point of View: Susan Faye Dent, MD
In a joint ASCO/ICOS (International Cardio-Oncology Society) session presented at the 2023 Global Cardio-Oncology Summit, Dr. Anita Arnold and Dr. Krishnan Bhaskaran discussed the importance of understanding the impact of cancer therapy on the cardiovascular health of women. Medical oncologist...
Advanced NSCLC: Adding Canakinumab to First-Line Chemoimmunotherapy
As reported in the Journal of Clinical Oncology by Tan et al, the phase III CANOPY-1 trial has shown no survival benefits with the addition of canakinumab to first-line pembrolizumab plus chemotherapy in patients with advanced/metastatic non–small cell lung cancer (NSCLC) without EGFR or ALK...
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer
As reported in The New England Journal of Medicine by Kathleen N. Moore, MD, and colleagues, the phase III MIRASOL trial has shown improved progression-free and overall survival with mirvetuximab soravtansine-gynx vs chemotherapy in previously treated patients with folate receptor–alpha...
W. Kimryn Rathmell, MD, PhD, Begins Work as 17th Director of the NCI
On December 18, W. Kimryn Rathmell, MD, PhD, began her work as the 17th Director of the National Cancer Institute (NCI). Dr. Rathmell was selected by President Biden to succeed Monica M. Bertagnolli, MD, FACS, FASCO, who left NCI to become the Director of the National Institutes of Health (NIH) on...
Luca Gianni, MD, on Locally Advanced, HER2-Positive Breast Cancer: New Data on Neoadjuvant Therapy and Atezolizumab
Luca Gianni, MD, of Milan’s Fondazione Michelangelo, discusses findings from the APTneo Michelangelo trial, which showed that adding atezolizumab to chemotherapy and trastuzumab plus pertuzumab did not significantly increase the rate of pathologic complete response (pCR) in women with HER2-positive ...
Combination Treatment That Skips Chemotherapy May Be Effective for Older Patients With Philadelphia Chromosome–Positive ALL
Older patients with Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL) who were not candidates for the standard treatment of intensive chemotherapy had a median overall survival of 6.5 years on an alternative regimen of dasatinib and blinatumomab, according to long-term results...
